Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 639-642

  Spanaki, A ^a   Perdikogianni, C ^a   Linardakis, E ^a   Kalmanti, M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Acute leukemia; Children; Molecular markers; PRAME

Indexed keywords

PRAME ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR; TESTIS;

ACUTE DISEASE; ADOLESCENT; ANTIGENS, NEOPLASM; CHILD; CHILD, PRESCHOOL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; NEOPLASM, RESIDUAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34147166486     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.006     Document Type: Article

References (16)

1. Pui C.H., and Evans W.E. Acute lymphoblastic leukaemia. N Engl J Med 339 (1998) 605-615
2. Loeb D.M., and Arceci R.J. What is the optimal therapy for childhood AML?. Oncology 16 (2002) 1057-1066
3. Ikeda H., Lethe B., Lehmann F., Van Baren N., Baurain J.F., De Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
4. Tajeddine N., Gala J.L., Louis M., Van Schoor M., Tombal B., and Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 65 (2005) 7348-7355
5. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signalling. Cell 122 (2005) 835-847
6. Neumann E., Engelsberg A., Decker J., Storkel S., Jaeger E., Huber C., et al. Heterogenous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?. Cancer Res 58 (1998) 4090-4095
7. Matsushita M., Yamazaki R., Ikeda H., and Kawakami Y. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for haematological malignancies. Leuk Lymphoma 44 (2003) 439-444
8. Van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells is expressed in acute leukemia cells. Br J Haematol 102 (1998) 1376-1379
9. Proto-Siqueira R., Falcão R.P., De Souza C.A., Ismael S.J., and Zago M.A. The expression of PRAME in chronic lymphoproliferative disorders. Leukemia Res 27 (2003) 393-396
10. Steinbach D., Hermann J., Viehmann S., Zintl F., and Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukaemia. Cancer Genet Cytogenet 133 (2002) 118-123
11. Steinbach D., Viehmann S., Zintl F., and Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukaemia. Cancer Genet Cytogenet 138 (2002) 89-91
12. Tajeddine N., Millard I., Gailly P., and Gala J.L. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 44 (2006) 548-555
13. Steinbach D., Schramm A., Eggert A., Onda M., Dawczynski K., Rump A., et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukaemia. Clin Cancer Res 12 (2006) 2434-2441
14. Paydas S., Tanriverdi K., Yavuz S., et al. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79 (2005) 257-261
15. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukemia. Br J Haematol 112 (2001) 916-926
16. Spanaki A., Linardakis E., Perdikogianni C., Stiakaki E., Morotti A., Cilloni D., et al. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukaemia. Leuk Res 31 (2007) 570-572